Planetary health investing and biotech investing are more alike than most practitioners in either camp realize. Yet the two ecosystems have largely evolved in parallel, developing their own governance norms, financing conventions, and public-market strategies. That separation is a missed opportunity. 

The biotech sector is experiencing the most severe downturn of at least the last 20 years. There have been many other downturns in the more recent past, but this one is different. Here Peter Kolchinsky discusses why - and how we’ll rebound.